Location out of bounds

Atypical hemolytic uremic syndrome (aHUS)

Client Services

Email 800-245-3117 x 6250 Request Information Online Ordering Portal Forms & Requisitions Accreditations and Licenses

Accelerating treatment through critical precision diagnostics.

Versiti Diagnostic Labs offers a comprehensive approach to the diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS). By using next-generation genetic sequencing, and a multidisciplinary approach, we provide confidence in precision test results for every patient.

More about aHUS

  • Overview

    Atypical hemolytic uremic syndrome (aHUS) is a severe genetic disease that presents as a systemic thrombotic microangiopathy (TMA); patients typically exhibit non-immune hemolytic anemia, thrombocytopenia and organ dysfunction, and most often, renal disease. Sequence analysis of the genes associated with aHUS is useful to confirm diagnosis, assess familial risk, and direct potential therapeutic decisions.

  • Approach

    Streamlined evaluation to guide treatment decisions without delay.

    By adding thorough analysis of complement and regulatory genes relevant in aHUS and DDD to our current panel of genetic and plasma-based assays of ADAMTS13, we are able to offer a comprehensive laboratory panel for the evaluation of patients with TMA. This panel provides a comprehensive genetic analysis of patients with TMA with a turnaround time of 28 days. Rapid definitive diagnosis of these patients would enable physicians to accelerate the start of definitive treatment and enable improvement in patient care.

ic-arrow-right
x

This website uses cookies to ensure you get the best experience on our website. Learn more